Skip to main content

HCC 17: Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic

HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic, is one of the 115 payment categories in the CMS-HCC V28 model. 78 ICD-10-CM codes map to it in the payment year 2027 mapping, and a documented diagnosis in the category adds a relative factor of 4.209 to the risk score of a community, non-dual, aged beneficiary (3.995 disabled, 1.952 institutional). It sits at the top of its hierarchy, so no other category overrides it and it in turn overrides HCC 18, HCC 19, HCC 20, HCC 21, HCC 22, HCC 23. In its hierarchy, it overrides HCC 18 (2.341, -1.868), so a record coding both is paid this category's factor alone.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ICD-10-CM to HCC mapping: PY2027 initial ICD-10-CM mappings (dates of service 2026) (payment year 2027); CMS-HCC V28 model software: CMS-HCC V28 software V2826.115.T2 (PY2027 initial) (payment year 2027). Next CMS release: PY2028 advance notice (February 2027) and the PY2027 midyear final mapping (spring 2027).

Mapped ICD-10-CM codes
78
Factor, community non-dual aged
4.209
Factor, institutional
1.952
Hierarchy
Top of hierarchy
Disease group
Neoplasm

Relative factors by segment

Each segment is a separate regression; the factor is added to the beneficiary's demographic factors and other categories, then normalized and reduced by the coding intensity adjustment before it meets the plan's base rate. A factor of 1.000 equals the expected cost of an average beneficiary.

CMS-HCC V28 relative factors for HCC 17 by model segment
SegmentModel codeRelative factor
Community, non-dual, agedCNA_HCC174.209
Community, non-dual, disabledCND_HCC173.995
Community, full-benefit dual, agedCFA_HCC173.896
Community, full-benefit dual, disabledCFD_HCC174.235
Community, partial-benefit dual, agedCPA_HCC173.946
Community, partial-benefit dual, disabledCPD_HCC174.103
Long-term institutionalINS_HCC171.952

Hierarchy

Hierarchical condition categories pay only the most severe manifestation of a disease. HCC 17 is the most severe category in its hierarchy. When HCC 17 is present it drops HCC 18 (Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid), HCC 19 (Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers), HCC 20 (Lung and Other Severe Cancers), HCC 21 (Lymphoma and Other Cancers), HCC 22 (Bladder, Colorectal, and Other Cancers), HCC 23 (Prostate, Breast, and Other Cancers and Tumors), so documenting the less severe condition alongside it adds nothing to payment but still matters for the clinical record.

ICD-10-CM codes that map to HCC 17

78 codes map to this category in the PY2027 initial mapping, concentrated in the C92 (15), C78 (13), C84 (11), C79 (10), C94 (9), C7B (8) code families. CMS built that mapping from codes valid in FY2025 and FY2026, and descriptions are the CMS mapping descriptions. None of these codes was deleted in the October 1, 2026 update.

ICD-10-CM codes mapped to HCC 17 in the CMS PY2027 initial mapping
ICD-10-CMDescription
C77.1Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C77.8Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C78.00Secondary malignant neoplasm of unspecified lung
C78.01Secondary malignant neoplasm of right lung
C78.02Secondary malignant neoplasm of left lung
C78.1Secondary malignant neoplasm of mediastinum
C78.2Secondary malignant neoplasm of pleura
C78.30Secondary malignant neoplasm of unspecified respiratory organ
C78.39Secondary malignant neoplasm of other respiratory organs
C78.4Secondary malignant neoplasm of small intestine
C78.5Secondary malignant neoplasm of large intestine and rectum
C78.6Secondary malignant neoplasm of retroperitoneum and peritoneum
C78.7Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80Secondary malignant neoplasm of unspecified digestive organ
C78.89Secondary malignant neoplasm of other digestive organs
C79.00Secondary malignant neoplasm of unspecified kidney and renal pelvis
C79.01Secondary malignant neoplasm of right kidney and renal pelvis
C79.02Secondary malignant neoplasm of left kidney and renal pelvis
C79.31Secondary malignant neoplasm of brain
C79.32Secondary malignant neoplasm of cerebral meninges
C79.40Secondary malignant neoplasm of unspecified part of nervous system
C79.49Secondary malignant neoplasm of other parts of nervous system
C79.70Secondary malignant neoplasm of unspecified adrenal gland
C79.71Secondary malignant neoplasm of right adrenal gland
C79.72Secondary malignant neoplasm of left adrenal gland
C7B.00Secondary carcinoid tumors, unspecified site
C7B.01Secondary carcinoid tumors of distant lymph nodes
C7B.02Secondary carcinoid tumors of liver
C7B.03Secondary carcinoid tumors of bone
C7B.04Secondary carcinoid tumors of peritoneum
C7B.09Secondary carcinoid tumors of other sites
C7B.1Secondary Merkel cell carcinoma
C7B.8Other secondary neuroendocrine tumors
C84.10Sezary disease, unspecified site
C84.11Sezary disease, lymph nodes of head, face, and neck
C84.12Sezary disease, intrathoracic lymph nodes
C84.13Sezary disease, intra-abdominal lymph nodes
C84.14Sezary disease, lymph nodes of axilla and upper limb
C84.15Sezary disease, lymph nodes of inguinal region and lower limb
C84.16Sezary disease, intrapelvic lymph nodes
C84.17Sezary disease, spleen
C84.18Sezary disease, lymph nodes of multiple sites
C84.19Sezary disease, extranodal and solid organ sites
C84.1ASezary disease, in remission
C92.00Acute myeloblastic leukemia, not having achieved remission
C92.01Acute myeloblastic leukemia, in remission
C92.02Acute myeloblastic leukemia, in relapse
C92.30Myeloid sarcoma, not having achieved remission
C92.31Myeloid sarcoma, in remission
C92.32Myeloid sarcoma, in relapse
C92.50Acute myelomonocytic leukemia, not having achieved remission
C92.51Acute myelomonocytic leukemia, in remission
C92.52Acute myelomonocytic leukemia, in relapse
C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
C92.61Acute myeloid leukemia with 11q23-abnormality in remission
C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
C92.A1Acute myeloid leukemia with multilineage dysplasia, in remission
C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse
C93.00Acute monoblastic/monocytic leukemia, not having achieved remission
C93.01Acute monoblastic/monocytic leukemia, in remission
C93.02Acute monoblastic/monocytic leukemia, in relapse
C94.00Acute erythroid leukemia, not having achieved remission
C94.01Acute erythroid leukemia, in remission
C94.02Acute erythroid leukemia, in relapse
C94.20Acute megakaryoblastic leukemia not having achieved remission
C94.21Acute megakaryoblastic leukemia, in remission
C94.22Acute megakaryoblastic leukemia, in relapse
C94.40Acute panmyelosis with myelofibrosis not having achieved remission
C94.41Acute panmyelosis with myelofibrosis, in remission
C94.42Acute panmyelosis with myelofibrosis, in relapse
D46.22Refractory anemia with excess of blasts 2
E34.00Carcinoid syndrome, unspecified
E34.01Carcinoid heart syndrome
E34.09Other carcinoid syndrome
I31.31Malignant pericardial effusion in diseases classified elsewhere
J91.0Malignant pleural effusion
R18.0Malignant ascites

New FY2027 codes in this family (CMS mapping pending)

The October 1, 2026 update created 2 codes for conditions that were previously reported with a code mapping to HCC 17; the FY2027 conversion table names that earlier code in the last column. CMS has not mapped the new codes yet, because the PY2027 initial mapping only covers codes valid in FY2025 and FY2026, so treat their category as pending until CMS posts a mapping that includes FY2027 codes.

ICD-10-CM codes new on October 1, 2026 whose predecessor maps to HCC 17
New ICD-10-CMDescriptionPreviously coded as
C78.31Secondary malignant neoplasm of larynxC78.39
C78.32Secondary malignant neoplasm of pharynxC78.39

Every new and deleted code for FY2027, with its CC level and MS-DRGs, is in the FY2027 ICD-10-CM/PCS code changes report.

What changed from V24

The payment year 2025 mapping carries both models for the same codes. Of the 79 codes it maps to V28 HCC 17, 3 had no V24 payment category (new to payment under V28); the largest source is V24 HCC 8 (Metastatic Cancer and Acute Leukemia) with 57 codes. The V28 community, non-dual, aged factor is 4.209 against 2.659 for V24 HCC 8.

V24 categories that the HCC 17 codes belonged to (PY2025 mapping)
V24 HCCV24 categoryCodes now in HCC 17V24 codes with no V28 HCCV24 factor (CNA)
8Metastatic Cancer and Acute Leukemia570 of 822.659
10Lymphoma and Other Cancers110 of 5950.675
12Breast, Prostate, and Other Cancers and Tumors40 of 2710.150
9Lung and Other Severe Cancers30 of 1101.024
46Severe Hematological Disorders15 of 951.372

V24 and V28 number their categories independently, so the same diagnosis usually carries a different HCC number in each model. The V24 to V28 crosswalk report lists every category pair, and the glossary explains the 2020 CMS-HCC V24 model and the V28 model that replaced it.

Inpatient groups where these diagnoses land

Appendix B of the v44 MS-DRG Definitions Manual places the codes in this category in the logic of 60 MS-DRGs. The groups with the most shared codes are below; a hospital stay coded with one of these diagnoses groups there when it is the principal diagnosis, or when the DRG's logic uses it as a qualifying secondary diagnosis.

MS-DRGs whose logic lists the most HCC 17 codes
MS-DRGTitleShared codes
DRG 820Lymphoma and Leukemia with Major O.R. Procedures with MCC41
DRG 821Lymphoma and Leukemia with Major O.R. Procedures with CC41
DRG 822Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC41
DRG 834Acute Leukemia with MCC24
DRG 835Acute Leukemia with CC24
DRG 836Acute Leukemia without CC/MCC24
DRG 837Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent with MCC24
DRG 838Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent24
DRG 839Chemotherapy with Acute Leukemia as Secondary Diagnosis without CC/MCC24
DRG 850Acute Leukemia with Other Procedures24

Local coverage policies that list these diagnoses

Medicare Administrative Contractors name covered ICD-10-CM codes in the billing and coding articles attached to their LCDs. These policies share the most codes with HCC 17 in the current Medicare Coverage Database export (one policy per topic; overlap counts after each). For the services these policies govern, the same diagnoses are covered indications, so the documentation that supports the category also supports the claim for the service.

Where these codes sat in the V22 model

The V28 recalibration renumbered and regrouped categories; this table shows which legacy V22 categories the same ICD-10 codes belonged to, which is the quickest way to reconcile a V22-era HCC gap list with the current model.

V22 categories that the HCC 17 codes mapped to
V22 HCCCodes
857
1011
93
123
461

Part D: the RxHCC categories of these codes

The same diagnoses feed the RxHCC model, which adjusts Medicare Part D payments. Of the 78 codes in HCC 17, 75 also map to a prescription drug category and 3 carry none; the categories are below, and the RxHCC hub has their 2027 MA-PD, PDP and PACE factors.

RxHCC V08 categories that the HCC 17 codes map to
RxHCCCategoryCodes
RxHCC 19Leukemias and Other Hematologic Cancers39
RxHCC 18Secondary Cancer of Lung, Liver, Brain, and Other Sites22
RxHCC 20Lung, Kidney, and Other Cancers; Secondary Cancer of Lymph Nodes and Other Sites7
RxHCC 17Secondary Cancer of Bone and Kidney4
RxHCC 22Prostate, Breast, Bladder, and Other Cancers and Tumors3

Capturing and defending the category

A category counts for a payment year when a mapped diagnosis is documented at least once during the data collection year by an acceptable provider type at a face-to-face or audio-video encounter, and when the note shows the condition was monitored, evaluated, assessed or treated. Chronic conditions do not carry forward: a category that is not re-documented in the year drops out of the score, which is why annual wellness visits and problem-list reconciliation are where most recapture happens. Risk adjustment data validation audits sample enrollees and ask for the medical record behind each submitted category; an unsupported category is removed and, under the extrapolation rules, the error rate is applied across the contract. The QuickIntell risk adjustment product surfaces suspected and unsupported categories from the chart, and the HCC hub lists every V28 category with its factor and code count.

For teams evaluating QuickIntell software

Evaluate risk adjustment review software

For teams reviewing documentation across a cohort, explore source evidence, proposed findings, reviewer decisions and audit handoffs. Confirm the program, payment year and model scope during evaluation. A category lookup is not a patient-specific coding or payment determination.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

Which ICD-10 codes map to HCC 17?

78 ICD-10-CM codes map to HCC 17 in the CMS PY2027 initial mapping, for example C77.1 Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; C77.8 Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions; C78.00 Secondary malignant neoplasm of unspecified lung; C78.01 Secondary malignant neoplasm of right lung. The full list is on this page; a code counts only when it is documented at a face-to-face or video encounter in the data collection year and supported by the record.

How much does HCC 17 add to a risk score?

The V28 relative factor for HCC 17 is 4.209 for a community, non-dual, aged beneficiary, 3.896 for full-benefit dual aged, 3.995 for non-dual disabled and 1.952 for long-term institutional members. A factor of 1.000 equals the expected annual cost of an average beneficiary, so the category's share of the payment follows the plan's base rate for that segment.

Does HCC 17 count together with related categories?

No. Within a hierarchy only the most severe category is paid. HCC 17 is the most severe category in its hierarchy, and it drops HCC 18, HCC 19, HCC 20, HCC 21, HCC 22, HCC 23 when it is present.

What has to be documented for HCC 17 to be valid?

One of the 78 mapped codes (such as C77.1) must be recorded by an acceptable provider type during a face-to-face or audio-video encounter in the service year, with the note showing that the condition (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) was monitored, evaluated, assessed or treated. Risk adjustment data validation audits recover payment for categories the record does not support, so the code on the claim and the assessment in the note must match.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Relative factors and mappings are reproduced from the CMS risk adjustment model files as an operational reference. Payment depends on the plan's base rate, normalization, the coding intensity adjustment and the enrollee's segment. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.